RESEARCH

β-cell function in black South African women: exploratory associations with insulin clearance, visceral and ectopic fat

Melony C Fortuin-de Smidt1,2, Amy E Mendham1,2, Jon Hauksson3, Ali Alhamud4,5, Darko Stefanovski6, Olah Hakim7, Jeroen Swart1, Louise M Goff2, Steven E Kahn8, Tommy Olsson9 and Julia H Goedecke1,2

1Division of Exercise Science and Sports Medicine, Department of Human Biology, University of Cape Town, Cape Town, South Africa
2Non-Communicable Diseases Research Unit, South African Medical Council, Tygerberg, South Africa
3Department of Radiation Sciences, Radiation Physics and Biomedical Engineering, Umeå University, Umeå, Sweden
4Department of Human Biology, MRC/UCT Medical Imaging Research Unit, University of Cape Town, Cape Town, South Africa
5The Modern Pioneer Center and ArSMRM for MRI Training and Development, Tripoli, Libya
6Department of Clinical Studies, New Bolton Centre, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, USA
7Department of Diabetes, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King’s College London, London, UK
8Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA
9Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden

Correspondence should be addressed to M C Fortuin-de Smidt: mcfortuindesmidt@gmail.com

Abstract

The role of ectopic fat, insulin secretion and clearance in the preservation of β-cell function in black African women with obesity who typically present with hyperinsulinaemia is not clear. We aim to examine the associations between disposition index (DI, an estimate of β-cell function), insulin secretion and clearance and ectopic fat deposition. This is a cross-sectional study of 43 black South African women (age 20–35 years) with obesity (BMI 30–40 kg/m²) and without type 2 diabetes that measured the following: DI, insulin sensitivity (SI), acute insulin response (AIRg), insulin secretion rate (ISR), hepatic insulin extraction and peripheral insulin clearance (frequently sampled i.v. glucose tolerance test); pancreatic and hepatic fat, visceral adipose tissue (VAT) and abdominal s.c. adipose tissue (aSAT) volume (MRI), intra-myocellular (IMCL) and extra-myocellular fat content (EMCL) (magnetic resonance spectroscopy). DI correlated positively with peripheral insulin clearance (β = 55.80, P = 0.002). Higher DI was associated with lower VAT, pancreatic fat and soleus fat, but VAT explained most of the variance in DI (32%). Additionally, higher first phase ISR (P = 0.033) and lower hepatic insulin extraction (P = 0.022) were associated with lower VAT, independent from SI rather than with ectopic fat. In conclusion, peripheral insulin clearance emerged as an important correlate of DI. However, VAT was the main determinant of a lower DI above ectopic fat deposits. Importantly, VAT, but not ectopic fat, is associated with both lower insulin secretion and higher hepatic insulin extraction. Prevention of VAT accumulation in young black African women should, therefore, be an important target for beta cell preservation.

Key Words

- β-cell function
- hepatic insulin extraction
- peripheral insulin clearance
- insulin secretion
- ectopic fat
Introduction

The acute insulin response (AIRg) relative to the prevailing level of insulin sensitivity (SI) described by the disposition index (DI) estimates the β-cell function, which is a key component in the pathogenesis of type 2 diabetes (T2D) (1). The primary events in the development of T2D may differ between black Africans and their white counterparts. Indeed, black Africans without T2D present with lower SI and hyperinsulinaemia, characterized by greater fasting insulin and AIRg in comparison to white individuals (2). In some cases, the AIRg response is exaggerated for the level of SI (3), resulting in a higher DI. Determinants of SI in black African populations have been studied extensively but there is limited evidence on the determinants of hyperinsulinaemia and its components, namely insulin secretion rate (ISR) and insulin clearance.

A lower hepatic insulin extraction (FEh) is found in black African women (4) which contributes towards a high AIRg (5), but how it relates to DI is unknown. In addition, the relative contribution of insulin clearance and insulin secretion to a high AIRg has only been reported in African–American children (5), but studies in black African adults with obesity and without T2D are lacking. Further, while the liver is the main organ involved in insulin clearance and clears approximately 50–70% of insulin during the first pass through the liver (6), insulin is also cleared by peripheral tissue such as the kidneys, muscle and adipose tissue, amongst others. However, the association of peripheral insulin clearance (CLp) with β-cell function needs further clarification.

Few studies have assessed associations between measures of β-cell function and VAT (7, 8, 9) and ectopic fat deposition (10, 11) in African–Americans, but no studies have been undertaken in an African cohort, which is required to determine if this phenotype is robust. Indeed, studies from Africa and the USA have consistently shown that black populations present with lower ectopic fat accumulation compared to white populations (10, 12, 13), together with hyperinsulinaemia (2) and paradoxically a higher prevalence of T2D. Whether black African populations exhibit a greater sensitivity to ectopic fat accumulation or whether ectopic fat is not an important correlate of β-cell function and its components requires further elucidation. Accordingly, this study aimed to evaluate the correlates of β-cell function, assessed by DI, focusing on hyperinsulinaemia (insulin secretion, FEh and CLp) and its association with ectopic fat depots in black South African women with obesity.

Materials and methods

Research design

This study was a cross-sectional analysis of baseline data obtained from a randomized, controlled exercise intervention study, for which the study design and methods have been published previously (14). Participants were recruited from low socio-economic areas in Cape Town, South Africa. Ethical permission was obtained from the University of Cape Town Human Research Ethics Committee. The trial was registered in the Pan African Clinical Trial Registry (PACTR201711002789113).

Participants

Black African (self-reported ancestry with both parents of isiXhosa descent) women with obesity (BMI 30–40 kg/m²) that fulfilled the following inclusion criteria were enrolled: age 20–35 years, stable weight (<5 kg change in weight in the last 6 months), using injectable contraception (depot medroxyprogesterone acetate, 400 mg) for a minimum of 2 months prior to testing. Different types of hormonal contraception (injectables compared to oral contraception) have differential effects on fasting glucose and insulin levels (15). In Khayelitsha, where most of our participants reside, 83% of women use injectable contraceptives and in the majority (75%), the method of contraception is determined by the healthcare provider (16). Therefore, to minimize the effect of hormonal fluctuations on our study findings, our inclusion criteria ensured participants were all using the same contraceptive method based on the standard of care in the public health system. Participants were excluded if they had any known diseases (e.g. HIV (HIV rapid negative), hypertension (BP ≥ 140/90 mmHg), diabetes (HbA1c > 6.5%), anaemia (haemoglobin <12 g/dL)), pregnant, lactating or smoking. After written informed consent was obtained, patients were screened for inclusion.

Body composition

Anthropometry included weight, height, hip and waist circumferences were measured using standardized methods. Whole-body composition was measured by dual-energy X-ray absorptiometry (DXA; Discovery-W®, software version 12.7.3.7; Hologic, Bedford, MA) for the analyses of sub-total body (whole body minus head) fat mass and fat-free soft tissue mass, as well as trunk and leg mass (expressed as per cent of sub-total body fat mass) (17).
Ectopic and central fat quantification

Pancreatic, hepatic and skeletal muscle (soleus, tibialis anterior) fat content, VAT and abdominal s.c. adipose tissue (aSAT) volumes were analysed using a 3 Tesla whole-body human MRI scanner (MAGNETOM Skyra; Siemens Medical Solutions) using a two-point Dixon method as described previously (14). Soleus and tibialis anterior intra-myocellular (IMCL) and extra-myocellular (EMCL) fat content were determined by magnetic resonance spectroscopy (MRS) using a point-resolved spectroscopy sequence with the following parameters: TR/TE 3000/33 ms, bandwidth 2000 Hz, 80 averages with voxel dimensions of 15 × 15 × 15 mm^3.

For the determination of hepatic, pancreatic and skeletal muscle fats, VAT and aSAT obtained by MRI, a fat fraction map was created and calculated as the fat signal over the sum of the water and fat signals. A region of interest (ROI) was drawn on seven consecutive slices in the right lobe of the liver. In the soleus and tibialis anterior muscles, an ROI was drawn on seven consecutive slices with a method adapted from Machann et al. (18). Pancreatic fat was determined by drawing one circular 1 cm^2 ROI in the head, body and tail of the pancreas to calculate the average (19). The methods for determining VAT and aSAT volumes were previously published (20). The above-mentioned methods, to quantify hepatic (21), pancreatic (22) and skeletal muscle fat (23) and VAT and aSAT (24), have previously been reported to have high precision.

Determination of S_I and β-cell function

An FSIGT allows for the determination of the acute insulin response after an i.v. glucose load (25). After 20 min, insulin is infused to suppress the endogenous insulin production which enables the evaluation of the effect of insulin on glucose disappearance. An FSIGT was used in this study because it provides measures of the AIRg as well as S_I and it is less labour intensive compared to the clamp method and does not require a steady-state. Additionally, the FSIGT shows a good correlation to the hyperglycaemic clamp (26). The FSIGT was conducted after an overnight fast (10–12 h). Glucose (50% dextrose, 11.4 g/m^2 body surface area) was infused at 0 min over a 60 s period. At 20 min, human insulin (0.02 unit/kg; NovoRapid, Novo Nordisk Limited) was infused over 5 min at a constant rate. Thirty-two blood samples were drawn over 240 min for the determination of plasma glucose and serum insulin and C-peptide.

Biochemical analyses

Fasting whole blood was collected and analysed for HbA1c using HPLC (Meharini Diagnostics, Florence, Italy). Plasma glucose concentrations were measured using a colorimetric assay (Randox (Pty) Ltd, Gauteng, South Africa). Serum insulin and C-peptide concentrations were determined by an immunochemiluminometric assay (IMMULITE 1000 immunoassay system, Siemens Healthcare (Pty) Ltd).

Mathematical modelling

The minimal model of glucose kinetics was used to calculate S_I, AIR_g and glucose effectiveness (27). S_I is a measure of the fractional disappearance of glucose for a given insulin concentration achieved by uncoupling the glucose and insulin responses. Glucose effectiveness is a measure of the ability of glucose to enhance its own uptake. AIR_g is the incremental area under the insulin curve in response to i.v. glucose over the first 10 min and reflects the first phase insulin response. DI is a measure of the insulin response to glucose relative to the prevailing level of S_I (AIR_g × S_I) which gives an index of whether the insulin response is adequate for the level of S_I (1). The ISR was determined by C-peptide deconvolution using a 2-compartmental model with standard kinetic parameters for individuals with obesity (28). The incremental area-under curve (AUC), above baseline, for ISR, glucose, insulin and C-peptide were calculated using the trapezoidal rule for the first 10 min and the entire 240 min of the FSIGT are referred to as the first phase AUC (ISR_{first phase}) and the total AUC (ISR_{total}), respectively.

FE_I and CLP were calculated using a method previously described by Polidori et al. (29). Hepatic insulin clearance was described using both linear and saturable kinetics. The linear model estimated a single parameter for hepatic insulin clearance (FE_I), while the saturable model estimated two parameters (Vmax and Km). The linear model described the hepatic insulin clearance well (fractional standard deviation <5%) in 91% (39/43) of participants. In addition, the linear model described the plasma insulin values with a mean normalized root square error (NMSE) ± s.D. of 8.3 ± 2.14%. The parameters of the models were estimated using WinSAAM (30).

Statistical analysis

Data were analysed using STATA 12.0 (College Station, TX, USA). Data analysis included those that completed an
FSIGT \((n = 43)\). The cohort was divided into tertiles based on the DI, calculated as \(S_I \times \text{AIRg} \times \text{DI}_{\text{low}} / \text{DI}_{\text{intermediate}} / \text{DI}_{\text{high}}\). Normally and non-normally distributed data were expressed as mean ± s.d. and median (25–75th percentile), respectively. Differences between DI tertiles were determined using one-way ANOVA with a Bonferroni post hoc test or Kruskal–Wallis test with the Dunn post hoc test for normally and non-normally distributed data, respectively. An exploratory analysis, to determine the associations between DI and its components and central and ectopic fat depots, was conducted using Pearson (normally distributed variables) and Spearman (non-normally distributed variables) correlations and, therefore, no corrections for multiple correlations were performed. Linear regression was performed with the transformed variables to determine the association between DI components and central fat depots. Since \(S_I\) may confound the associations of AIRg, ISR and FE\(_i\) with central fat depots, we adjusted for \(S_I\).

Results

Subject characteristics of the overall sample and by DI tertiles

A hyperbolic relationship between \(S_I\) and AIRg, the main components of DI, is presented in Fig. 1 for the overall sample (A) and in each of the DI tertiles (B). The cohort had a median age of 23 (IQR 21–27) years and a mean BMI of 33.2 ± 2.8 kg/m\(^2\). Participant characteristics by DI tertile, as an estimate of \(\beta\)-cell function, are displayed in Table 1. The group with the highest DI were the most insulin sensitive \((\text{post hoc } P = 0.001)\) and had the highest glucose effectiveness \((\text{post hoc } P < 0.001)\) compared to the group with the lowest DI. AIRg and ISR\(_{\text{first phase}}\) showed no significant decline across DI tertiles \((\text{post hoc } P = 0.060)\) and \(P = 0.071\), respectively). In addition, the group with the highest DI had the highest CLp \((\text{post hoc } P = 0.001)\) and lowest FE\(_i\) \((\text{post hoc } P = 0.049)\) compared to those in the lowest DI tertile. Further, the highest DI had the lowest pancreatic and hepatic fat, and the lowest VAT and VAT-aSAT ratio, compared to those with the lowest DI.

Correlations of DI with AIRg, \(S_I\) and ISR

DI was positively associated with both its immediate components (AIRg: rho 0.372, \(P = 0.014\); \(S_I\) : rho 0.459, \(P = 0.020\)) and ISR\(_{\text{first phase}}\) (rho 0.350, \(P = 0.021\)).

Associations of DI and its components with CLp and FE\(_i\)

Further, in univariate analysis, DI was positively associated with CLp and inversely with FE\(_i\) which explained 23.4 and 16.8% of the variance in DI, respectively (Table 2). However, when both CLp and FE\(_i\) were placed in the model only CLp remained a significantly positive correlate of DI. \(S_I\) was not associated with FE\(_i\) \((P = 0.065)\) and CLp \((P = 0.881)\) in the univariate model (Table 2). The association between \(S_I\) and FE\(_i\) became significant when adjusted for CLp \((P = 0.038)\). AIRg was associated with CLp in the univariate analysis but after adjusting for FE\(_i\) and \(S_I\) this association was diminished (Table 2).

Contributions of FE\(_i\) and ISR\(_{\text{first phase}}\) to AIRg

In addition, we used linear regression models to determine the relative contributions of FE\(_i\) and ISR\(_{\text{first phase}}\) to AIRg, without and with adjustment for \(S_I\) (Table 3). In the univariate models, ISR\(_{\text{first phase}}\) explained more of the variance in AIRg compared to FE\(_i\), 81.9% and 57.6%, respectively. \(S_I\) explained 32% of the variance in AIRg (data not shown). In the multivariate model, FE\(_i\) and ISR\(_{\text{first phase}}\) were independently associated with AIRg, adjusted for \(S_I\).

Figure 1

Hyperbolic association between insulin sensitivity (\(S_I\)) and acute insulin response to glucose (AIRg) for overall sample (A) and by disposition index (DI) tertiles (B).
| Characteristics of participants by disposition index tertile. | DI_{low} (≤5073.4), n = 15 | DI_{Intermediate} (>5073.4 to ≤7933.2), n = 13 | DI_{high} (>7933.2), n = 15 | P value |
|---|---|---|---|---|
| **Age and anthropometry** | | | | |
| Age (years) | 24 (21–28) | 22 (21–28) | 23 (21–24) | 0.455 |
| Body weight (kg) | 85.1 ± 8.8 | 87.8 ± 6.3 | 87.1 ± 13.7 | 0.400 |
| BMI (kg/m²) | 33.3 ± 2.6 | 35.3 ± 2.1 | 33.6 ± 3.5 | 0.147 |
| Waist circumference (cm) | 103.1 ± 5.3 | 103.9 ± 8.5 | 105.8 ± 11.0 | 0.705 |
| Waist-hip ratio | 0.89 (0.84–0.95) | 0.89 (0.87–0.91) | 0.90 (0.85–0.94) | 0.899 |
| **Body composition and fat distribution** | | | | |
| Body fat mass (%) | 50.1 ± 2.8 | 51.3 ± 3.1 | 50.4 ± 4.5 | 0.660 |
| Fat free soft tissue mass (kg) | 36.9 (33.8–40.3) | 37.4 (35.8–38.8) | 38.7 (34.9–40.6) | 0.791 |
| Trunk fat mass (%) | 47.9 ± 4.7 | 47.3 ± 4.0 | 46.5 ± 4.7 | 0.684 |
| Leg fat mass (%) | 40.0 ± 5.2 | 40.6 ± 4.3 | 40.8 ± 5.2 | 0.901 |
| Android fat mass (%) | 8.5 ± 1.4 | 8.1 ± 0.8 | 7.9 ± 0.8 | 0.284 |
| Gynoid fat mass (%) | 18.5 ± 1.8 | 18.7 ± 2.0 | 18.4 ± 2.5 | 0.942 |
| VAT (cm²) | 1113.3 ± 317.9 | 931.6 ± 355.1 | 669.8 ± 229.1* | 0.002 |
| aSAT (cm²) | 5303.9 ± 1116.8 | 5741.4 ± 1105.2 | 5629.1 ± 2191.8 | 0.747 |
| VAT:aSAT | 0.20 (0.16–0.24) | 0.15 (0.11–0.21)^† | 0.13 (0.09–0.15)^† | 0.003 |
| **Ectopic fat** | | | | |
| Mean pancreatic fat (%) | 8.0 (7.3–9.0) | 7.4 (6.6–10.4) | 6.2 (5.2–6.4)^†,§ | 0.006 |
| Hepatic fat (%) | 5.6 (4.5–6.1) | 5.9 (4.5–8.4) | 4.5 (3.9–4.9)^†,§ | 0.023 |
| Soleus fat (%) | 10.7 (10.1–11.4) | 9.7 (8.8–11.6) | 9.4 (8.6–10.3) | 0.111 |
| Tibialis anterior fat (%) | 4.1 (3.3–5.7) | 4.2 (3.5–5.4) | 5.0 (2.6–6.1) | 0.953 |
| SIMCL (%) | 2.9 (2.5–3.9) | 2.9 (2.5–4.8) | 2.1 (1.3–3.1)^† | 0.055 |
| SEMCL (%) | 4.5 (4.2–12.8) | 5.1 (3.6–4.5) | 4.3 (3.6–5.6) | 0.410 |
| TIMCL (%) | 0.5 (0.3–0.8) | 0.4 (0.3–0.5) | 0.4 (0.3–0.5) | 0.288 |
| TEMCL (%) | 2.9 (1.1–4.7) | 2.6 (1.6–3.0) | 2.5 (1.5–4.2) | 0.815 |
| **Fasting metabolic parameters** | | | | |
| Fasting glucose (mmol/L) | 5.4 ± 0.9 | 5.0 ± 0.9 | 5.2 ± 0.6 | 0.411 |
| Fasting insulin (pmol/L) | 85.2 (63.9–119.1) | 82.5 (78–113.7) | 57.7 (38.6–88.5) | 0.107 |
| Fasting C-peptide (pmol/L) | 605.7 (572.6–744.8) | 733.2 (491.5–835.8) | 466.7 (382.3–787.8) | 0.218 |
| C-peptide/insulin_{basal} | 6.8 (6.3–8.4) | 8.4 (6.4–9.3) | 9.0 (7.7–10.9) | 0.087 |
| ISR_{basal} (pmol/min) | 78.7 (74.4–96.8) | 94.7 (62.9–102.4) | 62.4 (49.7–104.6) | 0.567 |
| HOMA2 IR% | 2.1 (1.7–2.9) | 2.0 (1.8–2.7) | 1.4 (1.0–2.2) | 0.149 |
| HOMA2 B% | 134.6 (97.5–204.3) | 182.6 (130.4–213.2) | 108.7 (85.2–149.1) | 0.133 |
| **HbA1c and FSIGT-derived measures** | | | | |
| HbA1c | 5.24 ± 0.36 | 5.19 ± 0.36 | 5.20 ± 0.43 | 0.829 |
| Disposition index (AU) | 3780 (2989–4527) | 6596 (6070–7119)^§ | 9995 (9247–13882)^§ | <0.001 |
| S_I (mU/L/min) | 1.94 (1.1–2.8) | 1.97 (1.4–3.1) | 3.1 (2.2–4.5)^† | 0.008 |
| AIRg (mU/L/min) | 2159 (1465–3159) | 2909 (2544–4870) | 3561 (4278–4514) | 0.064 |
| Sg (%/min) | 0.017 ± 0.008 | 0.024 ± 0.008 | 0.031 ± 0.008^§ | <0.001 |
| ISR_{first phase} (pmol/min) | 2692 (1909–4023) | 3624 (2826–4999) | 4049 (2758–4877) | 0.060 |
| ISR_{total} (pmol/min) | 4246 (3231–8095) | 5589 (4813–7913) | 4272 (3261–6500) | 0.365 |
| FEg (%) | 61.6 ± 11.9 | 54.5 ± 8.7 | 51.4 ± 9.4^† | 0.042 |
| CLP (mL/min/kg) | 74.7 (61.3–105.3) | 91.5 (77.1–125.8) | 128.9 (92.3–168.2)^† | 0.009 |

Mean (± s.d.) for normally distributed variables and median (IQR) for non-normally distributed variables. P value derived from ANOVA or Kruskal-Wallis, significant post hoc differences: † High DI compared to low DI; ‡High DI compared to intermediate DI; §Intermediate DI compared to low DI with P ≤ 0.05 deemed as statistically significant.

AIG, acute insulin response to glucose; aSAT, abdominal s.c. adipose tissue; CLP, peripheral insulin clearance; DI, disposition index; FEL, fractional hepatic insulin extraction; HOMA, homeostatic model assessment 2 of insulin resistance (IR) and beta cell function (B); ISR, insulin secretion rate; SEMCL, soleus extra-myocellular fat; SIMCL, soleus intra-myocellular fat; TEMCL, tibialis anterior extra-myocellular fat; TIMCL, tibialis anterior intra-myocellular fat; VAT, visceral adipose tissue. adipose tissue; SIMCL, soleus intra-myocellular fat; SEMCL, soleus extra-myocellular fat; TIMCL, tibialis anterior intra-myocellular fat; VAT, visceral adipose tissue. adipose tissue; SIMCL, soleus intra-myocellular fat; SEMCL, soleus extra-myocellular fat; TIMCL, tibialis anterior extra-myocellular fat; ISR, insulin secretion rate; HOMA, homeostatic model assessment 2 of insulin resistance (IR) and beta cell function (B); SI, insulin sensitivity; AIG, acute insulin response to glucose; Sg, glucose effectiveness; FE

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Table 2  Relationship of β-cell function and insulin sensitivity with hepatic and peripheral insulin clearance.

| Model | Variables | SqRT DI | β (P value) | R² |
|-------|-----------|---------|-------------|----|
| 1.    | FEₐ (%)  | -0.709 (0.010) | -0.016 (<0.001) | 0.576 |
| 2.    | ln CLp (mL/min/kg) | 55.80 (0.002) | 0.623 (0.004) | 0.204 |
| 3.    | FEₐ (%)  | -0.364 (0.222) | -0.015 (<0.001) | 0.579 |
| 4.    | ln CLp (mL/min/kg) | 42.78 (0.035) | 0.086 (0.630) | -0.001 (<0.001) |

| Model | Variables | Ln AIRg | β (P value) | R² |
|-------|-----------|---------|-------------|----|
| 1.    | ln ISR first phase | -0.016 ± 0.002 | -0.016 ± 0.002 | 0.576 |
| 2.    | Hepatic insulin extraction (%) | 0.813 ± 0.091 | 0.701 | <0.001 |
| 3.    | ln ISR first phase | -0.007 ± 0.002 | -0.314 | 0.001 |
| 4.    | ln S₂ (mU/L)⁻¹ min⁻¹ | 0.667 ± 0.094 | 0.574 | <0.001 |

| Model | Variables | Ln S₄ | β (P value) | R² |
|-------|-----------|-------|-------------|----|
| 1.    | ln ISR first phase | -0.007 ± 0.001 | -0.333 | <0.001 |
| 2.    | Hepatic insulin extraction (%) | -0.166 ± 0.053 | -0.203 | 0.004 |

P ≤ 0.05 regarded as statistically significant.

AIRg, acute insulin response to glucose; CLp, peripheral insulin clearance; DI, disposition index; FEₐ, fractional hepatic insulin extraction; ISR, insulin secretion rate; Ln, natural log; S₄, insulin sensitivity; SqRT, square root; β, linear regression coefficient.

DI and its components – associations with body fat distribution and ectopic fat

DI was not associated with fat mass (%), leg fat mass or aSAT (data not shown) but was negatively associated with VAT and the VAT-aSAT ratio (β = −167.4, P < 0.001). The unadjusted associations between DI and ectopic fat depots and VAT are shown in Fig. 2. DI was inversely correlated with pancreatic fat, total soleus fat and both soleus IMCL and EMCL. DI was not associated with tibialis anterior fat (β = −2.59, P = 0.887). In univariate analysis, VAT explained 32% of the variance in DI, while soleus IMCL explained 18.7%, soleus EMCL 10.9% and pancreatic fat 12%. Adjusting for age and fat mass (%) in multivariable models did not alter the models. Accordingly, the negative associations of DI with pancreatic fat (β = −62.9, P = 0.030), VAT (β = −0.037, P < 0.001), soleus fat (β = −50.0, P = 0.049), soleus IMCL (β = −41.3, P = 0.012) and soleus EMCL (β = −32.0, P = 0.047) remained. We explored the associations between DI and ectopic fat, independent of VAT and found that the associations of DI with pancreatic fat, hepatic fat, soleus fat and soleus IMCL were ameliorated to non-significance (P > 0.05) (data not shown). Instead, VAT remained a significant determinant of DI independent of any of the ectopic fat depots (data not shown).

The components of DI (S₄, AIRg, ISR first phase, FEₐ and CLp) were not associated with fat mass (%) or ectopic fat sites (P > 0.05) (data not shown). Rather, significant associations were found between the components of DI and central fat measures (Fig. 3 and Supplementary Table 1, see section on supplementary materials given at the end of this article). VAT was associated with lower S₄ and AIRg, as well as a lower ISR first phase and higher FEₐ. CLp was not associated with any central fat depots (data not shown).

Lastly, we explored the associations between VAT and ectopic fat depots (Fig. 3 and Supplementary Table 2). VAT was positively associated with pancreatic fat (rho 0.417, P = 0.007) and soleus IMCL (rho 0.403, P = 0.014) but was not associated with soleus EMCL (rho 0.121, P = 0.474) and hepatic fat (rho 0.300, P = 0.060). Moreover, pancreatic fat was positively associated with hepatic fat (rho 0.540, P < 0.001).

Discussion

The correlates of β-cell function, a critical factor in the pathogenesis of T2D, are incompletely understood, especially in black African populations who present with a phenotype of low S₄, hyperinsulinaemia and low ectopic fat deposition. Our study extends the existing evidence

Table 3  The contribution of insulin secretion and hepatic insulin extraction to acute insulin response to glucose.

| Model | Variables | β-coefficient ± S.E. | Partial beta | P | Model R² |
|-------|-----------|----------------------|--------------|---|---------|
| 1.    | ln ISR first phase | 0.99 ± 0.07 | – | <0.001 | 0.819 |
| 2.    | Hepatic insulin extraction (%) | -0.016 ± 0.002 | – | <0.001 | 0.576 |
| 3.    | ln ISR first phase | 0.813 ± 0.091 | 0.701 | <0.001 | 0.869 |
| 4.    | Hepatic insulin extraction (%) | -0.007 ± 0.002 | -0.314 | 0.001 | 0.898 |
| 5.    | ln S₄ | -0.007 ± 0.001 | -0.333 | <0.001 |
| 6.    | ln S₂ (mU/L)⁻¹ min⁻¹ | -0.166 ± 0.053 | -0.203 | 0.004 |

AIRg, acute insulin response to glucose; ISR, insulin secretion rate; Ln, natural log; S.E., standard error; S₄, insulin sensitivity.
by demonstrating that DI was positively associated with CLp. Notably, the major correlate of AIRg was ISR_{first\ phase}, above insulin clearance. VAT emerged as the strongest correlate of DI, above and independent of pancreatic fat and soleus fat. Additionally, we showed that a higher VAT was also associated with a lower ISR_{first\ phase} and higher FE_{L}.

Thus, our findings suggest that VAT is a more important correlate of a lower DI than ectopic fat in this cohort, not only through its association with a lower SI but also through its relation with the AIRg downstream components, ISR and FE_{L} (Fig. 3).

**DI associates with peripheral insulin clearance**

Our study not only distinguishes between FE_{L} and CLp, which has only been done in a few studies in adults without T2D (4, 29, 31), but we also demonstrated a positive association between DI and CLp for the first time (Fig. 3). The reason for this relationship is unclear. Nevertheless, considering DI is based on the product of SI and AIRg, we can postulate two scenarios. First, a higher DI may be due to hyperinsulinaemia relative to the level of SI. However, hyperinsulinaemia has been associated with lower insulin clearance in both adipose tissue (32) and muscle (33), due to reduced affinity of insulin receptors at these sites and is, therefore, an unlikely explanation for our finding of a higher CLp relative to higher DI. Secondly, a higher DI could be due to a greater SI in relation to the level of AIRg. In this scenario, a higher CLp may be due to enhanced binding of insulin to insulin receptors in peripheral tissues. Although a positive association has been demonstrated between SI and

---

**Figure 2**
Disposition index (DI) associations with (A) pancreatic fat (B) hepatic fat, (C) visceral adipose tissue, (D) soleus fat (E) soleus intra-myocellular fat (IMCL) and (F) soleus extra-myocellular fat (EMCL) in those with low DI (solid black triangles), intermediate DI (open circles) and high DI (solid black square). Regression line indicates significant association (P < 0.05) in the whole cohort, β (slope), r – correlation coefficients.

**Figure 3**
Graphical summary of the important correlates of disposition index (DI) shown in the present study. A higher DI was associated with a lower pancreatic and soleus intra-myocellular fat (IMCL), but these associations were not independent from VAT. A higher VAT was associated with lower first phase insulin secretion rate (ISR) and higher hepatic insulin extraction (FE_{L}). Accordingly, VAT is a more important correlate of a lower DI than ectopic fat in this cohort, not only through its association with a lower SI but also through its relationship with the acute insulin response (AIRg) and its downstream components, ISR and FE_{L}. Peripheral insulin clearance (CLp) was associated with DI and not SI. Positive association (+); negative association (−).
hepatic insulin clearance (34), no association between insulin internalization, a measure of insulin clearance, and $S_I$ was observed in rat adipocytes (32), whereas the association between $S_I$ and insulin clearance in muscle is unknown. However, in support of the second scenario, we showed that those with the highest DI and CLp were also more insulin sensitive but only exhibited a slightly higher AIRg compared to those with lower DI and CLp. Nevertheless, CLp was not associated with $S_I$ in our study but rather with the insulin secretory component. Further, we may also consider that the observed association between DI and CLp is in compensation for a lower FE_L, but this association remained independent of FE_L. We also evaluated the associations of CLp with ectopic fat deposition as possible explanation for the association with DI but found that CLp was not associated with skeletal muscle fat. Skeletal muscle fat has been associated with reduced $S_I$ (35), which may also affect CLp in the muscle. Further study is justified to evaluate the relationship between CLp and $S_I$ in the muscle, considering that the muscle is only secondary to the kidney in the proportion of insulin cleared in the periphery (36). Of note, CLp in our study is much higher compared to another study conducted in black American women (4). However, the acute insulin response in our cohort was twice as high as that observed in Piccinini et al. and may contribute to this discrepancy.

**Associations between DI and ectopic fat**

Preservation of β-cell function is critical for delaying the onset of T2D. We, therefore, investigated, first, whether ectopic fat accumulation may explain the variance in DI and secondly, we assessed the associations of ectopic fat with the components of DI. Our study demonstrated that a higher DI was associated with a lower pancreatic and soleus fat but these associations were not independent of VAT. A similar observation was found in overweight African–American and Hispanic adolescents (13 to 25 years old) without T2D (37). In contrast, a positive association between DI and pancreatic fat, adjusted for BMI and VAT, was shown in black African–American women (11). However, this study included participants with and without T2D, which may explain the incongruent findings. Our study extends the literature by showing that pancreatic fat was not associated with ISR\_first\_phase or with FE_L in black Africans. Notably, a positive association was found between pancreatic fat and VAT in our study (Fig. 3). Our findings, therefore, suggest that pancreatic fat may only be a marker of VAT accumulation and may not be detrimental to β-cell function in this cohort.

**Contribution of hepatic insulin clearance and ISR to AIRg**

The ability to maintain DI and prevent deteriorating glucose tolerance depends on the balance between AIRg and $S_I$ (1). However, there is no consensus on the mechanism of maintaining a higher AIRg, which is frequently observed in black African populations (2, 3). Some studies reported that a lower hepatic insulin clearance alone is responsible for a higher AIRg (38, 39), while others showed that both lower hepatic insulin clearance and higher ISR contribute towards a higher AIRg (3, 4). Notably, AIRg may be out of proportion for the level of $S_I$ and to assess the relative contribution of ISR\_first\_phase and insulin clearance to AIRg in this context, we need to adjust for $S_I$. Accordingly, a lower FE_L and higher ISR\_first\_phase were the main independent contributors towards a higher AIRg, but ISR\_first\_phase explained more of the variance in AIRg. Lowering hepatic insulin clearance is an important compensatory mechanism to reduce the strain on the pancreatic β-cells, which has been shown in canines (40). Indeed, we also noted a higher DI is associated with a lower FE_L which may be explained by the negative association between AIRg and FE_L (Fig. 3). Further, we showed that higher ISR associates with AIRg, independently of lower FE_L and $S_I$, suggesting that despite a lower FE_L, pancreatic β-cells may continue to secrete insulin at a higher rate, which may be detrimental to the longevity of the β-cell in this cohort.

**Associations of ISR and hepatic insulin clearance with ectopic fat**

The current study further examined the associations between the components of AIRg and ectopic fat. Previously, reduced hepatic insulin clearance and increased insulin secretion have been associated with hepatic fat accumulation (41). An association between fasting hepatic insulin clearance and hepatic fat was studied in African–American women (13), but the association between stimulated hepatic insulin clearance, which is a more physiological response, and hepatic fat has not been previously investigated in black African populations without T2D. We showed that hepatic fat was not associated with FE_L and ISR in black South African women with obesity. Therefore, in black African populations, hepatic fat may not be an important correlate...
of hepatic insulin clearance and insulin secretion prior to T2D, and also not in those with early T2D (42). Instead, we found that a lower ISRfirst phase and higher FEi were associated with higher VAT (Fig. 3). This highlights a novel mechanism to explain the association between AlRg and VAT since to the best of our knowledge, no previous study has evaluated the effect of central fat depots on FEi. In addition, evidence on the associations between central fat depots and ISR determined by C-peptide deconvolution is also limited in black African populations (9). We add to the literature by showing a negative association between VAT and ISRfirst phase independent of Sβ in premenopausal black South African women. Interestingly, black African women have lower VAT compared to other ethnicities (2, 3), but they have a greater propensity to increase VAT over time, with the greatest increase occurring in the 20–29-year age group (43). However, further studies are needed to confirm the effect of VAT on ISR in this cohort.

**Associations between Sï and ectopic fat**

We also assessed the association between Sï and ectopic fat and found no association between Sï and skeletal muscle or hepatic fat. These findings suggest that these ectopic fat depots are not important correlates of Sï in our study. However, we should consider that we measured whole body Sï, which could have diluted the associations with hepatic and soleus fat. Indeed, a small South African study found that in black South African women, hepatic fat was associated with hepatic Sï but not peripheral Sï (12). Furthermore, total soleus fat and soleus IMCL were associated with peripheral Sï but not hepatic Sï (12). Nevertheless, lower Sï was associated with higher VAT which may contribute to the observed inverse association between DI and VAT in this cohort (Fig. 3).

A major strength of this study is that ISR and both hepatic and peripheral clearance were determined using mathematical modelling, which has never been done before in an African cohort. Further, we assessed pancreatic, hepatic and skeletal muscle ectopic fat depots, as well as VAT and aSAT volumes using MRI. However, this study also has limitations. While we cannot exclude that only progesterone injectable contraception usage may have contributed to the high AlRg observed in this cohort (44), it is important to note that a high AlRg has been reported in African–American children prior to the use of contraception (5, 45) and in many other studies including African women in the USA (3, 46, 47) and SA (2). We did not determine glucose tolerance, and we did not distinguish between hepatic and peripheral Sï.

We have not corrected for multiple correlations which may have produced false positive associations. However, the focus was to explore the possible significant associations between variables and, therefore, we wanted to minimize false negative associations. Of note, the sample size was modest and may have contributed to a type II error. In addition, these findings are applicable to premenopausal, black South African women with obesity and may not be extrapolated to men or other races. Lastly, a causal relationship between variables cannot be determined from this cross-sectional study and further research is required to confirm these exploratory findings.

In conclusion, an original finding from this study was that DI was associated with CLp, independent from FEi. Further, while both FEi and ISRfirst phase independently contributed towards hyperinsulinaemia, ISRfirst phase was more important. Ectopic fat was not an important independent correlate of DI and its components. Rather, a key finding was that higher VAT was the principal correlate of a lower DI, above other ectopic fat depots. Additionally, the associations of higher VAT on the downstream components of DI, a lower ISRfirst phase and higher FEi may contribute to lower DI prior to T2D onset but requires further elucidation. Accordingly, the prevention of VAT accumulation, especially in young black African women should be an important target for β-cell preservation.

**Supplementary materials**

This is linked to the online version of the paper at https://doi.org/10.1530/EC-21-0153.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This study was funded by the National Research Foundation of South Africa (NRF), Competitive Programme for Rated Researchers (Grant no: 93577), the NRF/STINT Sweden/South Africa Research Collaboration Programme (UID: 106784), the South African Medical Research Council (SAMRC). M F is a recipient of SAMRC, through its Division of Research Capacity Development, Clinician Researcher Development PhD Scholarship Programme. The content hereof is the sole responsibility of the authors and does not necessarily represent the official views of the SAMRC. S K is supported in part by the United States Department of Veterans Affairs.

**Author contribution statement**

A M, J G, T D conceived and designed the study. M F, A M, J G, J S performed study procedures. M F, A A, J H, O H performed MRI fat quantification. M F, D S performed mathematical modelling. MF prepared figures and drafted
the manuscript. M F, A M, J G were involved in data analysis. M F, A M, J G, T O, J S, S K, J H, D S, L G, A A, O H read and edited the manuscript and approved the final version. M F, A M and J G are the guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements

The authors thank Nandipha Sinyanya, Ntombekhaya Zoneleni, Keitumetse Smouse and Hendriena Victor for their valuable contribution towards the study.

References

1 Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifling JL, Ward WK, Beard JC & Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993 42 1663–1672. (https://doi.org/10.2337/diab.42.11.1663)

2 Goedecke JH, Dave JA, Faulenbach MV, Utschneider KM, Lambert EV, West S, Collins M, Olsson T, Walker BR, Seckl JR, et al. Insulin response in relation to insulin sensitivity: an appropriate beta-cell response in black South African women. Diabetes Care 2009 32 860–865. (https://doi.org/10.2337/dc08-2048)

3 Chow CC, Perwial V, Csako G, Ricks M, Courville AB, Miller BV, Vega GL & Sumner AE. Higher acute insulin response to glucose may determine greater free fatty acid clearance in African-American women. Journal of Clinical Endocrinology and Metabolism 2011 96 2456–2463. (https://doi.org/10.1210/jc.2011-0532)

4 Piccinni E, Polidori DC, Gower BA & Bergman RN. Hepatic but not extrahepatic insulin clearance is lower in African-American than in European American women. Diabetes 2017 66 2564–2570. (https://doi.org/10.2337/db17-0413)

5 Gower BA, Granger WM, Franklin E, Shewchuk RM & Goran MI. Contribution of insulin secretion and clearance to glucose-induced insulin concentration in African-American and Caucasian children. Journal of Clinical Endocrinology and Metabolism 2002 87 2218–2224. (https://doi.org/10.1210/jc.2002-021746)

6 Toffolo G, Campioni M, Basu R, Rizza RA & Cobelli C. A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. American Journal of Physiology: Endocrinology and Metabolism 2006 290 E169–E176. (https://doi.org/10.1152/ajpendo.00473.2004)

7 Sumner AE, Farmer NM, Cochran CS, Seeking NG, Vaneksi K, Reynolds JC, Premkumar A & Boston RC. Obese premenopausal African-American women with normal and impaired glucose tolerance have a similar degree of insulin resistance but differ in beta-cell function. Diabetes Care 2001 24 1978–1983. (https://doi.org/10.2337/diacare.24.11.1978)

8 Wagenknecht LE, Langefeld CD, Schenzinger AL, Norris JM, Haffner SM, Saad MF & Bergman RN. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003 52 2490–2496. (https://doi.org/10.2337/diabetes.52.10.2490)

9 Chandler-Laney PC, Phadke RP, Granger WM, Mao J, Man CD, Cobelli C, Ovalle F, Fernandz JR & Gower BA. Adiposity and B-cell function: relationships differ with ethnicity and age. Obesity 2010 18 2086–2092. (https://doi.org/10.1038/oby.2010.44)

10 Szczepaniak LS, Victor RG, Mathur R, Nelson MD, Szczepaniak EW, Tye N, Chen I, Unger RH, Bergman RN & Lingvay I. Pancreatic steatosis and its relationship to beta-cell dysfunction in humans: racial and ethnic variations. Diabetes Care 2012 35 2377–2383. (https://doi.org/10.2337/dc12-0701)

11 Lingvay I. Ethnic diversity in beta-cell function susceptibility to pancreatic triglyceride levels: pilot investigation. Journal of Diabetes and Metabolism 2014 5 3. (https://doi.org/10.4172/2155-6156.1000348)

12 Goedecke JH, Keswell D, Weinreich C, Fan J, Hauksson J, Victor H, Utschneider K, Levitt NS, Lambert EV, Kahn SE, et al. Ethnic differences in hepatic and systemic insulin sensitivity and their associated determinants in obese black and white South African women. Diabetologia 2015 58 2647–2652. (https://doi.org/10.1007/s00125-015-3720-7)

13 Chung ST, La Cruz MG De, Aldana PC, Mbundo LS, DuBose CW, Onuzuuniu KE, Walter M, Gharib AM, Courville AB, Sherman AS, et al. Postprandial insulin response and clearance among black and white women: the federal women’s study. Journal of Clinical Endocrinology and Metabolism 2019 104 181–192. (https://doi.org/10.1210/jc.2018-01302)

14 Goedecke JH, Mendham AE, Clamp L, Nono Nankam PA, Fortuin-De Smidt MC, Phiri L, Mcklesfield LK, Keswell D, Woolberg NJ, Lecour S, et al. An exercise intervention to unravel the mechanisms underlying insulin resistance in a cohort of black South African women: protocol for a randomized controlled trial and baseline characteristics of participants. Journal of Medical Internet Research 2018 20 e75. (https://doi.org/10.2196/jmir.9098)

15 Berenson AB, Van Den Berg P, Williams KJ & Rahman M. Effect of injectable and oral contraceptives on glucose and insulin levels. Obstetrics and Gynecology 2011 117 41–47. (https://doi.org/10.1097/AOG.0b013e318202ac23)

16 Cooper D & Marks AS. Community-based distribution of contraception: a pilot project in Khayelitsha, Cape Town. Urbanisation and Health Newsletter 1996 30 49–55.

17 Goedecke JH, Mcklesfield LK, Levitt NS, Lambert EV, West S, Maertens G & Dave JA. Effect of different antiretroviral drug regimens on body fat distribution of HIV-infected South African women. AIDS Research and Human Retroviruses 2013 29 557–563. (https://doi.org/10.1089/aids.2012.0252)

18 Machann J, Bachmann OP, Brechtle K, Dahl DB, Wietek B, Klumpp B, Häring HU, Claussen CD, Jacob S & Schick F. Lipid content in the musculature of the lower leg assessed by fat selective MRI: intra- and inter-individual differences and correlation with anthropometric and metabolic data. Journal of Magnetic Resonance Imaging 2003 17 350–357. (https://doi.org/10.1002/jmri.10255)

19 Hakim O, Bonadonna RC, Mohandas C, Bilbao Z, Sunderland A, Boselli L, Alberti KGMM, Peacock JL, Umpleby AM, Edwards GC, et al. Associations between pancreatic lipids and beta-cell function in black African and white European men with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2019 104 1201–1210. (https://doi.org/10.1210/jc.2018-01809)

20 Shen W, Chen J, Gantz M, Velasquez G, Punyanitya M, Panyunyita M & Heymsfield SB. A single MRI slice does not accurately predict visceral and subcutaneous adipose tissue changes during weight loss. Obesity 2012 20 2458–2463. (https://doi.org/10.1038/oby.2012.168)

21 Hu F, Yang R, Huang Z, Wang M, Yuan F, Xiu C, Wei Y & Song B. 3D multi-echo dixon technique for simultaneous assessment of liver steatosis and iron overload in patients with chronic liver diseases: a feasibility study. Quantitative Imaging in Medicine and Surgery 2019 9 1014–1024. (https://doi.org/10.21037/qims.2019.05.20)

22 Heber SD, Hetterich H, Lorbeer R, Bayerl C, Machann J, Auwarter S, Storz C, Schlett CL, Nikolau K, Reiser M, et al. Pancreatic fat content by magnetic resonance imaging in subjects with prediabetes, diabetes, and controls from a general population without cardiovascular disease. PLoS ONE 2017 12 e0177154. (https://doi.org/10.1371/journal.pone.0177154)

23 Alltai H, Nardo L, Karampinos DC, Joseph GB, Yap SP, Baum T, Krug R, Majumdar S & Link TM. Comparison of clinical semi-quantitative assessment of muscle fat infiltration with quantitative...
assessment using chemical shift-based water/fat separation in MR studies of the calf of post-menopausal women. *European Radiology* 2012 22 1592–1600. (https://doi.org/10.1007/s00330-012-2404-7)

24 Bonekamp S, Ghosh P, Crawford S, Solga SF, Horska A, Brancati FL, Diehl AM, Smith S & Clark JM. Quantitative comparison and evaluation of software packages for assessment of abdominal adipose tissue distribution by magnetic resonance imaging. *International Journal of Obesity* 2008 32 100–111. (https://doi.org/10.1038/sj.ijo.0803696)

25 Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM & Bergman RN. MINMOD millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. *Diabetes Technology and Therapeutics* 2003 5 1003–1015. (https://doi.org/10.1089/152091503322641060)

26 Korytkowski MT, Berga SL & Horwitz MJ. Comparison of the minimal model and the hyperglycemic clamp for measuring insulin sensitivity and acute insulin response to glucose. *Metabolism: Clinical and Experimental* 1995 44 1121–1125. (https://doi.org/10.1006/metc.1995.0095)

27 Bergman RN, Prager R, Volund A & Olefsky JM. Equivalence of the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant, fat-fed canine model. *Journal of Clinical Investigation* 1987 79 790–800. (https://doi.org/10.1172/JCI112886)

28 Van Cauter E, Mestrez F, Sturis J & Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. *Diabetes* 1992 41 368–377. (https://doi.org/10.2337/db91.13.3.368)

29 Polidori DC, Bergman RN, Chung ST & Sumner AE. Hepatic and extrahepatic insulin clearance are differentially regulated: results from a novel model-based analysis of intravenous glucose tolerance data. *Diabetes* 2016 65 1556–1564. (https://doi.org/10.2337/db15-1373)

30 Stefanovski D, Moate PJ & Boston RC. WiMAAM: a windows-based compartmental modeling system. *Metabolism: Clinical and Experimental* 2003 52 1153–1166. (https://doi.org/10.1016/S0026-0495(03)00144-6)

31 Utzschneider KM, Kahn SE & Polidori DC. Hepatic insulin extraction based compartmental modeling system. *American Journal of Physiology: Endocrinology and Metabolism* 2007 292 E1581–E1589. (https://doi.org/10.1152/ajpendo.00351.2006)

32 Morgan RN, Kim SP, Catalano JK, Hsu IR, Chiu JD, Kabir M, Hucking K & Ader M. Why visceral fat is bad: mechanisms of the metabolic syndrome. *Obesity* 2006 14 (Supplement 1) 165–195. (https://doi.org/10.1038/oby.2006.277)

33 Hakim O, Bello O, Bonadonna RC, Mohandas C, Shojaee-Moradie F, Jackson N, Boselli L, Whittinger B, Shuaib H, Alberti KGMM, et al. Ethnic differences in intrahepatic lipid and its association with hepatic insulin sensitivity and insulin clearance between men of black and white ethnicity with early type 2 diabetes. *Diabetology and Metabolism* 2019 21 2163–2168. (https://doi.org/10.1111/dmab.13771)

34 Yeganshan MY, Scherzinger A, Haffner S, Norris JM, Bryer-Ash M & Wagenknecht LE. Five-year change in visceral adipose tissue quantity in a minority cohort: the insulin resistance atherosclerosis study (IRAS) family study. *Diabetes Care* 2009 32 1553–1555. (https://doi.org/10.2337/dc08-0336)

35 Jones CNO, Pei D, Stars P, Polonsky KS, Chen YDI & Reaven GM. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. *Journal of Clinical Endocrinology and Metabolism* 1997 82 1834–1838. (https://doi.org/10.1210/jcem.82.6.5397)

36 Tokarz VL, MacDonald PE & Klip A. The cell biology of systemic insulin function. *Journal of Cell Biology* 2018 217 2273–2289. (https://doi.org/10.1083/jcb.201802995)

37 Le KA, Ventura EE, Fisher JQ, Davis JN, Weigensberg MJ, Punyanitya M, Hu HH, Nayak KS & Goran MI. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. *Diabetes Care* 2011 34 485–490. (https://doi.org/10.2337/dc10-0760)

38 Osei K & Schuster DP. Ethnic differences in secretion, sensitivity, and hepatic extraction of insulin in black and white Americans. *Diabetic Medicine* 1994 11 755–762. (https://doi.org/10.1111/j.1464-5491.1994.tb00349.x)

39 Osei K, Schuster DP, Owusu SK & Amoah AGB. Race and ethnicity determine serum insulin and C-peptide concentrations and hepatic insulin extraction and insulin clearance: comparative studies of three populations of West African ancestry and white Americans. *Diabetology and Experimental* 1997 46 53–58. (https://doi.org/10.1016/S0026-0495(97)90003-9)

40 Kim SP, Ellmerer M, Kirklan EL & Bergman RN. B-cell ‘rest’ accompanies reduced first-pass hepatic insulin extraction in the insulin-resistant, fat-fed canine model. *American Journal of Physiology: Endocrinology and Metabolism* 2007 292 E1581–E1589. (https://doi.org/10.1152/ajpendo.00351.2006)

41 Bergman RN, Kim SP, Catalano JK, Hsu IR, Chiu JD, Kabir M, Hucking K & Ader M. Why visceral fat is bad: mechanisms of the metabolic syndrome. *Obesity* 2006 14 (Supplement 1) 165–195. (https://doi.org/10.1038/oby.2006.277)

42 Haikin O, Bello O, Bonadonna RC, Mohandas C, Shojaee-Moradie F, Jackson N, Boselli L, Whittinger B, Shuaib H, Alberti KGMM, et al. Ethnic differences in intrahepatic lipid and its association with hepatic insulin sensitivity and insulin clearance between men of black and white ethnicity with early type 2 diabetes. *Diabetology and Metabolism* 2019 21 2163–2168. (https://doi.org/10.1111/dmab.13771)

43 Hairson KG, Scherzinger A, Yoc C, Hanley AJ, McCorkle O, Hafnner S, Norris JM, Bryer-Ash M & Wagenknecht LE. Five-year change in visceral adipose tissue quantity in a minority cohort: the insulin resistance atherosclerosis study (IRAS) family study. *Diabetes Care* 2009 32 1553–1555. (https://doi.org/10.2337/dc09-0336)

44 Kahn HS, Curtis KM & Marchbanks PA. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. *Diabetes Care* 2011 34 26 216–225. (https://doi.org/10.2337/diabetes.26.1.216)

45 Piccinni F, Polidori DC, Gower BA, Fernandez JR & Bergman RN. Dissection of hepatic versus extra-hepatic insulin clearance: ethnic differences in childhood. *Diabetology and Metabolism* 2018 20 2869–2875. (https://doi.org/10.1111/dmab.13471)

46 Ellis AC, Alvarez JA, Granger WM, Ovalle F & Gower BA. Ethnic differences in glucose disposal, hepatic insulin sensitivity, and endogenous glucose production among African American and European American women. *Metabolism: Clinical and Experimental* 2012 61 634–640. (https://doi.org/10.1016/j.metabol.2011.09.011)

47 Gower LL, Darnell RE, Otter RA, Brown MA & Gower BA. Associations of free fatty acids with insulin secretion and action among African-American and European-American girls and women. *Obesity* 2010 18 247–253. (https://doi.org/10.1038/oby.2009.248)